-
May 31, 2023
Medpacto takes part in BIO 2023… will actively engage in discussions regarding the commercialization of its pipelines, exploring opportunities for out-licensing
-
May 22, 2023
Seong-jin Kim, the CEO of MedPacto, unveils innovative new drug candidate at the Korean Society for Bone and Mineral Research
-
May 18, 2023
MedPacto, successfully completed the Type C meeting with the U.S. FDA for its global Phase2b/3 clinical trial of Vactosertib + Keytruda combination therapy
-
Apr 26, 2023
Vactosertib in combination with KEYTRUDA® (pembrolizumab) for colorectal cancer patients reported a mOS of 15.8 months
-
Apr 10, 2023
MedPacto and Theragen Etex have come together to expand the anti-cancer drug business
-
Mar 21, 2023
MedPacto Announces Poster Presentation on Combination Treatment of Vactosertib with PRMT5 in Pancreatic Cancer at the 2023 AACR Annual Meeting
-
Mar 14, 2023
MedPacto participates in the '2023 BIO-Europe Spring'... accelerating commercialization including out-licensing
-
Mar 09, 2023
MedPacto has obtained a domestic patent for the manufacture of Vactosertib
-
Feb 16, 2023
MedPacto receives IND approval from the Ministry of Food and Drug Safety to evaluate the safety and efficacy of Vactosertib as a single agent in patients with osteosarcoma
-
Feb 15, 2023
The efficacy of the combination treatment of Vactosertib with PRMT5 in pancreatic cancer was published in an international journal Cell Death and Disease (IF: 8.469)
-
Feb 02, 2023
MedPacto, identified the mechanism of action of the protein associated with the regulation of spermatogonial stem cell self-renewal
-
Jan 25, 2023
MedPacto hires global healthcare expert Namchol Park, as the Executive Vice President(EVP)
-
Jan 17, 2023
MedPacto receives U.S. FDA Fast Track designation for vactosertib for the treatment of metastatic osteosarcoma
-
Dec 20, 2022
Vactosertib research paper is published in ‘Cancers’, an international academic journal indexed in SCIE
-
Nov 16, 2022
MedPacto granted a European patent for their diagnostic kit detecting cancer cells in the blood
-
Nov 03, 2022
MedPacto discovers the world's first mechanism of liver metastasis in gastric cancer cells
-
Oct 24, 2022
MedPacto, Announces the formation of the Clinical Advisory Board for speeding up its new drug development and out-licensing
-
Oct 10, 2022
Once at home on palliative care, a pediatric patient with osteosarcoma enjoys an active return to school and a prolonged progression-free period while on Vactosertib monotherapy.
-
Sep 30, 2022
Seongjin Kim, CEO of MedPacto, meets with Maryland Governor Larry Hogan
-
Sep 15, 2022
MedPacto, Receives Rare Pediatric Disease Designation from the U.S. FDA for osteosarcoma patients
-
Sep 14, 2022
MedPacto presents interim Phase 1b clinical results for Vactosertib in combination with FOLFOX at AACR Special Conference on Pancreatic Cancer
-
Aug 19, 2022
MedPacto receives IND approval from FDA to evaluate the safety and efficacy of Vactosertib as a single agent in patients with osteosarcoma
-
Jul 12, 2022
MedPacto, announces IND submission to U.S. FDA to evaluate safety and efficacy of Vactosertib as a single agent in patients with osteosarcoma.
-
May 27, 2022
MedPacto to present the abstract about the combination study of Vactosertib in pancreatic cancer at the American Society of Clinical Oncology Annual Meeting
-
May 11, 2022
SeongJin Kim, CEO of MedPacto, named keynote peaker for BioKorea 2022
-
Apr 11, 2022
MedPacto announces execution of investigator-initiated clinical trials for combination therapy in gastric cancer patients
-
Apr 08, 2022
MedPacto Announces Execution of a collaborative study Agreement for ‘Cancer Diagnostic Kit’ with Gangnam Severance Hospital
-
Mar 24, 2022
MedPacto hires global clinical expert Timothy R. Allen, Executive Vice President(EVP)
-
Feb 25, 2022
Seongjin Kim, CEO of MedPacto, defined the MOA of the chemoresistance-associated protein and potential predictive biomarker
-
Feb 23, 2022
UH Seidman Cancer Center to Launch First-Ever Trial of NK Therapy and Vactosertib in Treating Colorectal Cancer and Hematological Malignancies
-
Feb 14, 2022
MedPacto Announces Execution of a Clinical Trial Agreement for a NK Cell Combination Trial for Colorectal Patients
-
Feb 11, 2022
MedPacto, HITS team up for AI-based drug development
-
Jan 26, 2022
MedPacto to release the clinical trial design of combination study in patients with metastatic pancreatic ductal adenocarcinoma at ASCO GI
-
Jan 19, 2022
MedPacto, advance procedures for the global Phase 3 combination trial for the colorectal patients are going smoothly
-
Dec 14, 2021
MedPacto Announces Clinical Collaboration with MSD to Evaluate Vactosertib, an Investigational TGF-β Type I Receptor Inhibitor, in combination with KEYTRUDA® (pembrolizumab) in a Phase 3 Trial with Registrational Intent
-
Jun 04, 2020
MedPacto to test Vactosertib for treating NSCLC
-
Jun 03, 2020
[ASCO 2020 ④] MedPacto's Vactosertib combo treatment for desmoid tumors proved safe
-
Jan 15, 2019
Stock issuance
-
Dec 21, 2018
Keytruda Combination Trial Application Approval followed by Another Approval for the Vactosertib + Durvalumab Combination Trial Application
-
Dec 05, 2018
Stock issuance
-
Jul 24, 2018
MedPacto Announces Clinical Collaboration with MSD to Evaluate Vactosertib, an Investigational TGF-β Type I Receptor Inhibitor, in combination with KEYTRUDA® (pembrolizumab)
-
Jul 24, 2018
MedPacto Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
-
Jun 04, 2018
Announcement of the closing date of shareholder list
-
Mar 27, 2018
Stock issuance
-
Feb 08, 2018
Stock issuance
-
Dec 18, 2017
Stock issuance
-
Sep 06, 2016
Temporary meeting of the board of directors
-
Aug 25, 2016
The MedPacto Inc. board has appointed Dr. Seong-Jin Kim as a co-chief executive officer
-
Mar 07, 2016
Announcement: 3rd annual general meeting of stockholders
-
Sep 10, 2015
Collaboration with ANRT
-
Feb 11, 2015
Announcement: 2nd annual general meeting of stockholders
-
Aug 13, 2014
Temporary meeting of the board of directors
-
Feb 06, 2014
Announcement: An annual general meeting of stockholders
-
Nov 05, 2013
National OncoVenture (NOV) announces the support of development of MedPacto’s leading anticancer drug candidate, TEW-7197